8 results about "Naive T cell" patented technology

This invention discloses a preparation process for a homogeneous immunomodulatory polysaccharide from *Gynostemma pentaphyllum* and its application in the preparation of anti-melanoma drugs and immunomodulators, relating to the field of pharmaceutical manufacturing technology. The preparation process includes four steps: compound enzyme-ultrasound synergistic extraction, fractional alcohol precipitation to remove proteins, DEAE-52 ion exchange column chromatography, and Sephacryl S-400 gel permeation chromatography purification. The resulting homogeneous polysaccharide (GOP-3) has a weight-average molecular weight of 12±1 kDa and is composed of mannose, glucose, and galactose in a specific ratio. The GOP-3 of this invention has a weight-average molecular weight (Mw) of 12.8 kDa, a dispersion (Mw / Mn) < 1.2, a uronic acid content of 23.5%, a well-defined structure, and is suitable for drug application. Furthermore, GOP-3 can significantly promote the secretion of IL-12 by dendritic cells and induce the differentiation of naive T cells into Th1 cells. Simultaneously, compared with a full-dose PD-1 monoclonal antibody, the combination of GOP-3 and a half-dose monoclonal antibody not only reduces the risk of immune-mediated pneumonia caused by antibody drugs but also increases the tumor inhibition rate by more than 40%.

Methods for preparing T cells for cell therapy, compositions produced by said methods, and methods for administering said cells to a subject are provided. Specifically, this disclosure relates to the preparation of engineered T cells, such as those expressing genetically engineered receptors, such as genetically engineered antigen receptors, like engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. The methods are characterized by producing more consistent and / or predictable T cell products and / or lower toxicity compared to other methods. The provided methods include incubating cells under stimulating conditions to induce the expansion or proliferation of naive T cells in the stimulated composition compared to non-naive T cells, which in turn can lead to preferential transduction of cells derived from said naive T cells. The methods may also be characterized by reduced cost, fewer steps, and reduced resource consumption compared to other methods.

The invention relates to the field of immunotherapy, in particular to an engineered antigen presenting cell which contains a coding sequence of a multispecific nano antibody. And / or can express and / or secrete a multispecific nano antibody; a tumor-associated antigen is loaded on the carrier, and the tumor-associated antigen is selected from one or more of the following components: P53, Survivin, MUC1, hTERT or KRAS. The antigen presenting cell disclosed by the invention can activate immature T cells and effectively stimulate the effector function of the activated T cells on cancers.

The present disclosure provides methods for preparing improved populations of cells of the T lineage of, specifically, naive-like T cells that comprise naive T cells (TN), stem-cell like memory T cells (TSCM), and central memory T cells (TCM). The method is based on enrichment for cells expressing a marker of circulating innate lymphoid cell precursor cells. The present disclosure further provides populations of these naive-like T cells, compositions thereof, and uses thereof in treating immune-related disorders.

The application discloses a polypeptide capable of directionally enhancing thymus newborn T cells to kill breast cancer and application thereof, and a peptide segment sequence is NH2-KLLSLIKGVIVHRLEGVE-GPSL-KDMQLGR-CONH2. A Th cell epitope sequence (KLLSLIKGVIVHRLEGVE) is from a measles virus fusion protein 288-302 peptide segment (MVF), and a four-residue linker (GPSL) is behind the T cell epitope. The linker is integrated into the fusion peptide to help independent folding of the T cell epitope and a B cell epitope. A B cell epitope sequence is a C segment fragment (KDMQLGR) of C5a. The polypeptide of the application can inhibit breast cancer tumor growth, enhance thymus T cell function output, and enhance T cell directional killing function on breast cancer, has low toxic side effects, and can be applied to breast cancer treatment, thereby providing a new scheme and a new idea for breast cancer treatment.

The invention relates to the field of immunotherapy, in particular to an engineered antigen presenting cell which contains a coding sequence of a multispecific nano antibody. And / or can express and / or secrete a multispecific nano antibody; the invention discloses a tumor-associated antigen carrier, which is characterized by being loaded with tumor-associated antigens, the tumor-associated antigens are selected from one or more of P53, Survivin and MUC1, and the Survivin is connected with the P53 in series. The antigen presenting cell disclosed by the invention can activate immature T cells and effectively stimulate the effector function of the activated T cells on cancers.